MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance-Reference-Cited by-同舟云学术

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance

Published:2013-09-26 Issue:13 Volume:122 Page:2284-2285
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Varettoni Marzia¹,Zibellini Silvia¹,Arcaini Luca¹²,Boveri Emanuela³,Rattotti Sara¹,Pascutto Cristiana¹,Mangiacavalli Silvia¹,Gotti Manuel¹,Pochintesta Lara¹,Paulli Marco³²,Cazzola Mario¹²

Affiliation:

1. Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy

2. Department of Molecular Medicine, University of Pavia, Pavia, Italy

3. Anatomic Pathology Section, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/13/2284/1368409/2284.pdf

Reference6 articles.

1. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia.;Treon;N Engl J Med,2012

2. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms.;Varettoni;Blood,2013

3. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.;Xu;Blood,2013

4. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia.;Jiménez;Leukemia,2013

5. MYD88 L265P somatic mutation in IgM MGUS.;Landgren;N Engl J Med,2012

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

2. Good clinical response following Ibrutinib treatment of a rare case of lymphoplasmacytic lymphoma secreting IgA kappa paraprotein: A case report;Oncology Letters;2024-05-28

3. Waldenstrom Macroglobulinemia;Comprehensive Hematology and Stem Cell Research;2024

4. Ibrutinib in therapy of Waldenstrom’s macroglobulinemia: literature review and clinical observation;MD-Onco;2023-09-19

5. MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges;Hemato;2023-09-13